Evidence map›Paper›PMID 41732759›Full record

ArticleMolecular therapy. Oncology2026

EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer.

Gábor Bakos, Ulrike Bauder-Wüst, Jonathan Landry, Mareike Roscher, Beáta Ramasz, Frank Bruchertseifer, Alfred Morgenstern, Clemens Kratochwil, Vladimír Beneš, Martina Benešová-Schäfer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gábor BakosResearch Group Molecular Biology of Systemic Radiotherapy, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Ulrike Bauder-WüstResearch Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Jonathan LandryGenomics Core Facility, European Molecular Biology Laboratory (EMBL), 69117 Heidelberg, Germany.
Mareike RoscherService Unit for Radiopharmaceuticals and Preclinical Studies, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Beáta RamaszFlow Cytometry Core Facility, European Molecular Biology Laboratory (EMBL), 69117 Heidelberg, Germany.
Frank BruchertseiferEuropean Commission, Joint Research Centre (JRC), 76125 Karlsruhe, Germany.
Alfred MorgensternEuropean Commission, Joint Research Centre (JRC), 76125 Karlsruhe, Germany.
Clemens KratochwilDepartment of Nuclear Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Vladimír BenešGenomics Core Facility, European Molecular Biology Laboratory (EMBL), 69117 Heidelberg, Germany.
Martina Benešová-SchäferResearch Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted radionuclide therapy and targeted alpha therapy directed at prostate-specific membrane antigen (PSMA) represent emerging treatment modalities for metastatic castration-resistant prostate cancer (mCRPC). However, therapeutic resistance remains a significant barrier to their clinical success. We discovered that dynamic changes in cell surface levels of epithelial cell adhesion molecule (EpCAM) and PSMA can serve as predictive biomarkers in late-stage mCRPC patients treated with the beta-minus-particle-emitting [

Indexed as

circulating tumor cellsCTCsEpCAMepithelial cell adhesion moleculegene expression analysisliquid biopsymCRPCmetastatic castration-resistant prostate cancerprostate-specific membrane antigenPSMAsurface marker dynamicstargeted alpha therapytreatment resistancetreatment response predictionTαT

Identifiers

PMID41732759
PMCPMC12925578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.